Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. - Wikidata - awgldk - TriplyDB

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

http://www.wikidata.org/entity/Q43821315

about

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.High burden of RSV hospitalization in very young children: a data linkage study.Residues in the heptad repeat a region of the fusion protein modulate the virulence of Sendai virus in mice Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.Genomewide association analysis of respiratory syncytial virus infection in mice.Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.Epidemiology of respiratory syncytial virus infection in preterm infants.Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phas Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea.Use of Medical Resources by Preterm Infants Born at Less than 33 Weeks' Gestation Following Discharge from the Neonatal Intensive Care Unit in Korea.Palivizumab in the prophylaxis of respiratory syncytial virus infection.Clinical Decision Support and Palivizumab: A Means to Protect from Respiratory Syncytial Virus An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases.Prophylaxis of respiratory syncytial virus in Canada in 2003.Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants.Palivizumab prophylaxis in 'late preterm' newborns.Therapeutic antibodies as a treatment option for dengue fever.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Incidence of Respiratory Disease During the First Two Years of Life in Children with Hemodynamically Significant Congenital Heart Disease in Italy: A Retrospective Study.Respiratory Tract Infection and Risk of Hospitalization in Children with Congenital Heart Defects During Season and Off-Season: A Swedish National Study.Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals.Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-risk infants.Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.Adherence and outcomes: a systematic review of palivizumab utilization.Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar.Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Respiratory syncytial virus risk factors in late preterm infants.

P2860

Q26830864-81EE1F1A-C6E6-43FD-89EA-F74068FB8A5B Q30245434-71F878C7-A2D9-4F14-9175-A4C293A58AA1 Q31029754-8E7533B2-43C4-445E-ADC5-3882342FD5B1 Q33558419-3CB21DC4-019E-4419-9E9F-93CD9C8C91B0 Q33558475-EBE587A1-1847-436B-B15C-4FA611457722 Q33610003-D0F404A4-1265-47DB-A3F3-90B2EF29A4EC Q33648868-58B98F2F-0592-4272-A862-4386CEBC6DE2 Q33809443-439DFC51-63BD-4513-BC89-B69AE4639C58 Q34457791-6E38D397-FB0B-4B0B-B096-F053EFB57957 Q35022776-657C3403-4303-4E28-939E-CD59AFE05B15 Q35673550-F5CD3F1A-DFEE-4DBF-BDDD-CF60DF9FC2DA Q35778606-90AAF942-4583-4166-A8E4-403FC7580EF9 Q35980935-36B32DA3-F7A5-40CB-86E4-E0BAF00C03B4 Q36172421-B4DC6BE7-DDFE-4821-A247-E957AED6B3DB Q36258838-6E811459-60DF-4198-B8BA-AFBB2BEDCB1F Q36269402-1CE975BA-8E8E-4B31-BFDA-594D9B5C7B6A Q36269470-CA316FA2-F7FE-4F9A-AB60-9A5E93E3D789 Q36278040-A1F144E2-5B99-442B-83FB-25F9F32200EE Q36438581-D7FB2794-DB91-4910-A48F-CF43D2980BDC Q36444590-9B0788F1-42F7-451C-B1C9-04C911FDDCFF Q36837007-87D92685-E0F4-47D0-9356-203338F54E64 Q36989863-186A080C-C6DA-4320-8D7F-9144C7C80131 Q37290618-5EBF15A5-D562-4DAE-B89E-B29803A5F937 Q37318542-F06D4B61-6071-4F3E-BB31-ED41805C7079 Q37481321-52149953-D0BC-44C5-A4DE-E201900A8E07 Q37586891-BC5B12BF-0F94-4C2F-B878-2A157D0265C5 Q37778833-98B2970B-7DBC-4DFC-AFDF-411E6EBDB20B Q38149195-40EF0F9B-C120-40E4-A822-525B80676A7B Q38671952-D46C1643-3A7B-492C-B9BB-EAF084DBE29D Q39442518-BF3F99C8-E4DD-4B6B-89CE-90119180008C Q40709529-1315B199-9991-4708-85CA-9A96BBDA892C Q42225156-16D8C310-1F00-4868-ADB9-4AECA63AE70A Q44480572-E846E2CC-F51B-4053-9DB7-114C1F613F21 Q45375474-A658B80C-4FE1-4EA0-8B1B-F720E38E36FC Q45396238-B2DA1B6B-DA31-48A6-AE3E-8295457B353F Q47582466-F8E891EC-DCF6-4FD1-82F3-35C4C1A8DD57 Q49474232-DC80ABBD-44EE-4CA6-A07E-675AC893CF50 Q49720574-92E024D2-0331-4748-A10D-C91E5DA6B22F Q50262223-56E90C90-0B62-4C5D-9B81-24A483244D54 Q53183759-73706E13-3C34-4028-8177-A234493E1398

P2860

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry.

http://www.wikidata.org/entity/Q43821315

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Palivizumab prophylaxis of res ...... Palivizumab Outcomes Registry.

@en

Palivizumab prophylaxis of res ...... Palivizumab Outcomes Registry.

@nl

type

label

Palivizumab prophylaxis of res ...... Palivizumab Outcomes Registry.

@en

Palivizumab prophylaxis of res ...... Palivizumab Outcomes Registry.

@nl

prefLabel

Palivizumab prophylaxis of res ...... Palivizumab Outcomes Registry.

@en

Palivizumab prophylaxis of res ...... Palivizumab Outcomes Registry.

@nl

P1433

Q43821315-B7915F89-4829-4593-A451-CDC2F9A44D66

P1476

Q43821315-CD3F84A9-51E4-40ED-B4C6-EACFA0EBCDB3

P2093

Q43821315-024B9E61-D5BA-48E6-9177-4EE01290A3E9

Q43821315-06F6A9BC-0192-43F1-827C-F5B9B4D376AB

Q43821315-08572A6C-986B-4378-A0A4-842ACACB9C3C

Q43821315-086E75F2-4800-4B3F-9BD1-D0719E23B434

Q43821315-087DD92C-9A6C-44EC-A2E7-169352577673

Q43821315-0B3A232F-1305-4205-91F1-B53A05092F0F

Q43821315-0BBDF7A6-1A6B-4242-9008-005DDBD33657

Q43821315-0BF448FD-840F-412E-8F0E-F2BCC4CBDD7C

Q43821315-0C81DE93-BC14-43DD-BA6D-0E4728B67A57

Q43821315-0C98DB52-D0E9-4C12-9FA6-0C0485EFB1CB

P304

Q43821315-847781CB-0944-4F67-8F5A-550650230868

P31

Q43821315-B9999CBB-F90D-42C5-A3CA-B6F226A3F1D6

P356

Q43821315-F217AA35-26D6-4578-BBB4-2432DACF6967

P433

Q43821315-69587BB2-065D-48F0-814C-7958A26ABF6F

P478

Q43821315-37CAC672-27A3-4A09-96AB-2B678C674407

P577

Q43821315-D4A748D8-6616-407C-841E-0BD6550149AD

P698

Q43821315-6259172E-D69E-4AE3-9B0A-1621FC5B02CC

P356

P1433

Pediatric Pulmonology

P1476

Palivizumab prophylaxis of res ...... Palivizumab Outcomes Registry.

@en

P2093

Alexandra Fetter-Zarzeka

http://www.w3.org/2001/XMLSchema#string

Allan Stanford

http://www.w3.org/2001/XMLSchema#string

Allen Aaronson

http://www.w3.org/2001/XMLSchema#string

Amanda Busey

http://www.w3.org/2001/XMLSchema#string

Andrew A Rzepka

http://www.w3.org/2001/XMLSchema#string

Andrew Gelfand

http://www.w3.org/2001/XMLSchema#string

Antoinette Gatti

http://www.w3.org/2001/XMLSchema#string

Arden Quintin

http://www.w3.org/2001/XMLSchema#string

Ben Guedes

http://www.w3.org/2001/XMLSchema#string

Beverly P Giordano

http://www.w3.org/2001/XMLSchema#string

P304

484-489

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PPUL.10288

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12746948

http://www.w3.org/2001/XMLSchema#string